The delisting notice is a material negative event for a $2M market cap company. Monitor the September 25, 2026 compliance plan submission deadline. If the plan is accepted, the stock may stabilize near current levels; if rejected or if the company fails to make progress, delisting procedures will begin, likely driving the stock to near-zero. The clinical progress on ONP-002 is early-stage and does not offset the existential listing risk.
Price Chart
Executive Summary
Oragenics received a delisting notice from NYSE American on August 26, 2026, for failing to meet stockholders' equity requirements ($3.7M vs. $4M/$6M thresholds). The company must submit a compliance plan by September 25, 2026, with a cure period until February 25, 2028. While the press release highlights continued Phase IIa enrollment (9 participants dosed) and FDA engagement for its lead concussion candidate ONP-002, the delisting risk and micro-cap status ($2M market cap) dominate the outlook. The stock now trades with a '.BC' designation, signaling below-compliance status.
Key Facts
- Received delisting notice from NYSE American for non-compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide.
- Reported stockholders' equity of $3.7M at June 30, 2026, below the $4M and $6M thresholds.
- Must submit a plan of compliance by September 25, 2026; cure period extends to February 25, 2028.
- Common stock will trade with a '.BC' designation indicating below-compliance status.
- Phase IIa trial for ONP-002 (concussion) has dosed 9 participants across 3 active Australian sites.
- Company received FDA responses on its Type B meeting request and aims to submit an IND by end of 2026.
- This is the same listing standard the company previously regained compliance with in October 2025.
- Market cap is approximately $2M, with top institutional holders including Geode ($13,750) and Jane Street ($7,414).
Financial Impact
Stockholders' equity of $3.7M is $300K below the $4M threshold and $2.3M below the $6M threshold. Delisting would severely impair access to public capital markets and reduce liquidity.
Risk Factors
- Delisting if compliance plan is not accepted or milestones are not met by February 25, 2028
- Inability to raise equity capital to fund operations or regain compliance
- Clinical trial failure or regulatory setback for ONP-002
- Extremely low market cap ($2M) and institutional ownership (top holder at $13,750) indicate minimal liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (OGEN) — Batch item 1 | 0001493152-26-040645 |
| Document: 0001493152-26-040645-index.html | 0001493152-26-040645 |
| Document: 0001493152-26-040645.txt | 0001493152-26-040645 |
| 8-K Filing (OGEN) — Batch item 4 | 0001493152-26-040645 |
| Document: 0001493152-26-040645-index.html | 0001493152-26-040645 |
| Document: 0001493152-26-040645.txt | 0001493152-26-040645 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 5w ago | 8-K | $0.5000 $0.4469 | ▼ −10.62% | ▼ −13.80% | $0.4000 (−20.00%) |
Aug 28, 2026 8w ago | 8-K | $0.5098 $0.4800 | ▲ +5.85% | ▲ +5.66% | $0.4000 (+21.54%) |
May 20, 2026 22w ago | DEFA14A | $0.5900 $0.5882 | ▼ −0.31% | ▼ −0.64% | $0.4000 (−32.20%) |
May 19, 2026 22w ago | 8-K | $0.5700 $0.6100 | ▲ +7.02% | ▲ +6.03% | $0.4000 (−29.82%) |
May 7, 2026 24w ago | 8-K | $0.6100 $0.6100 | · 0.00% | ▼ −3.14% | $0.4000 (−34.43%) |
Apr 13, 2026 28w ago | 8-K | $0.6800 $0.5600 | ▼ −17.65% | ▼ −25.38% | $0.4000 (−41.18%) |
Mar 25, 2026 30w ago | Press Release | $0.5800 $0.6400 | ▼ −10.34% | ▲ +0.32% | $0.4000 (+31.03%) |
Mar 23, 2026 31w ago | EFFECT | $0.6800 $0.6600 | ▼ −2.94% | ▼ −10.36% | $0.4000 (−41.18%) |
Mar 11, 2026 32w ago | 8-K | $0.9600 $0.6000 | ▼ −37.50% | ▼ −39.48% | $0.4000 (−58.33%) |
Mar 11, 2026 32w ago | Press Release | $0.8800 $0.6200 | ▼ −29.55% | ▼ −30.07% | $0.4000 (−54.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers